S. 527 · 119th Congress

Prescription Pricing for the People Act of 2025

Introduced on Feb 11, 2025 by Chuck Grassley (R-IA). 13 cosponsors, 6 of them from another party. Latest action (Apr 10, 2025): Placed on Senate Legislative Calendar under General Orders. Calendar No. 42.

Stage
Reported by committee
Introduced
Feb 11, 2025
Cosponsors
13
6 from the other party
Policy area
Commerce
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. Reported by committee
  3. 3Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

A bill to require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes.

Subjects

  • Business ethics
  • Business records
  • Competition and antitrust
  • Congressional oversight
  • Consumer affairs
  • Health care costs and insurance
  • Health information and medical records
  • Inflation and prices
  • Prescription drugs
  • Retail and wholesale trades
  • Supply chain

Summary

By the Congressional Research Service (Introduced in Senate, Feb 11, 2025). Public domain.

Prescription Pricing for the People Act of 2025

This bill requires the Federal Trade Commission (FTC) to report about anticompetitive practices and other trends within the pharmaceutical supply chain that may impact the cost of prescription drugs.

The report must address whether pharmacy benefit managers (PBMs) (1) reimburse pharmacies owned by the PBM at a higher price than other pharmacies, and (2) implement formulary designs to increase the market share of higher-cost prescription drugs or depress the market share of lower-cost prescription drugs.

The FTC also must provide recommendations to increase transparency in the supply chain, prevent anticompetitive practices, and ensure that consumers benefit from cost savings or efficiencies that result from mergers and consolidations.

Additionally, the FTC must report the number and nature of complaints the FTC receives relating to an allegation of anticompetitive conduct by a manufacturer of a sole-source drug.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Chuck GrassleyR-IASponsor

Democrats · 6

Republicans · 7

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Feb 11, 2025Introduced in Senate
  2. Feb 11, 2025 · SenateRead twice and referred to the Committee on the Judiciary.
  3. Apr 3, 2025 · SenateCommittee on the Judiciary. Ordered to be reported without amendment favorably.
  4. Apr 10, 2025Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
  5. Apr 10, 2025 · SenateCommittee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
  6. Apr 10, 2025 · SenatePlaced on Senate Legislative Calendar under General Orders. Calendar No. 42.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. AMERICAN COLLEGE OF RHEUMATOLOGY6 reports
    $560K reported (all issues)
  2. American Medical Association6 reports
    $36.2M reported (all issues)Federal contractor: AMERICAN MEDICAL ASSOCIATION$371K in contracts, FY2026AI match · 99%
  3. COUNCIL FOR INNOVATION PROMOTION (C4IP)6 reports
    $500K reported (all issues)
  4. NATIONAL ASSOCIATION OF CHAIN DRUG STORES, INC.6 reports
    $2.4M reported (all issues)
  5. NATIONAL COMMUNITY PHARMACISTS ASSOCIATION6 reports
    $1.9M reported (all issues)Federal contractor: NATIONAL COMMUNITY PHARMACISTS ASSOCIATIONAI match · 100%
  6. PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA6 reports
  7. BIOTECHNOLOGY INNOVATION ORGANIZATION5 reports
    $7.7M reported (all issues)
  8. Viatris (Mylan, Inc)5 reports
    $300K reported (all issues)
  9. Families USA Foundation, Inc.4 reports
    $38K reported (all issues)
  10. INDEPENDENT PHARMACY COOPERATIVE4 reports
    $170K reported (all issues)Federal contractor: INDEPENDENT PHARMACY COOPERATIVEAI match · 99%
  11. KAISER FOUNDATION HEALTH PLAN INC.3 reports
    $1.6M reported (all issues)Federal contractor: KAISER FOUNDATION HEALTH PLAN OF WASHINGTONAI match · 97%
  12. PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION3 reports
    $10.5M reported (all issues)
  13. SOLENO THERAPEUTICS, INC.2 reports
    $100K reported (all issues)
  14. AARP1 report
    $6.6M reported (all issues)
  15. PFIZER INC.1 report
    $4.2M reported (all issues)Federal contractor: PFIZER INCAI match · 100%

Reports filed in 2025, 2026.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 10, 2026 · loaded Oct 10, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 10, 2026 · loaded Oct 10, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.